Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ampligen Will Be Early Test Of FDA Consolidation Of Chronic Fatigue Drug Reviews

Executive Summary

FDA’s decision to consolidate oversight for chronic fatigue syndrome treatments in the Division of Pulmonary, Allergy and Rheumatology Products will face an early test with Hemispherx Biopharma Inc.’s expected submission of an amended NDA for its investigational agent Ampligen in the third quarter.
Advertisement

Related Content

FDA Uses AdComm Process To Shine Light On Ampligen’s Troubled Development
FDA Takes Dim View Of Ampligen For Chronic Fatigue Syndrome
Hemispherx Ampligen Advisory Cmte. Will Be Early Test Of FDA Focus On Chronic Fatigue Syndrome
Chronic Fatigue Syndrome Drug Development Efforts Get A Boost From FDA
Anti-Infective Product Development Is Focus Of Latest FDA Drug Review Reorg
Anti-Infective Product Development Is Focus Of Latest FDA Drug Review Reorg
Hemispherx Hopes To Ride Retrovirus Discovery To Ampligen Approval
Office Of New Drugs Reorganization Should Better Balance Workload, FDA Says
Chronic Fatigue Drug Moving Slowly: Hemispherx's Ampligen Gets "Complete Response"
Hemispherx Ampligen NDA Plans Could Pose Challenge For FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS053078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel